Loading clinical trials...
Loading clinical trials...
An Open-label, Single Arm Phase II Study of DFV890 to Assess the Safety, Tolerability and Efficacy in Participants With Familial Cold Auto-inflammatory Syndrome (FCAS)
Conditions
Interventions
DFV890
Locations
3
United States
Novartis Investigative Site
La Jolla, California, United States
Novartis Investigative Site
Paris, France
Novartis Investigative Site
Tübingen, Germany
Start Date
September 20, 2021
Primary Completion Date
December 13, 2022
Completion Date
May 5, 2023
Last Updated
October 9, 2024
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions